US 12,077,585 B2
Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
Rajkumar Ganesan, Blue Bell, PA (US); John Lee, North Wales, PA (US); Jinquan Luo, Malvern, PA (US); Theresa McDevitt, Warminster, PA (US); Fei Shen, Collegeville, PA (US); Degang Song, Wynnewood, PA (US); Raymond Brittingham, Spring House, PA (US); Sathyadevi Venkataramani, Blue Bell, PA (US); Sanjaya Singh, Blue Bell, PA (US); Yonghong Zhao, Eagleville, PA (US); Fang Yi, Collegeville, PA (US); and Sherry Lynn La Porte, Horsham, PA (US)
Assigned to Janssen Biotech, Inc., Horsham, PA (US)
Filed by Janssen Biotech, Inc., Horsham, PA (US)
Filed on Jul. 23, 2020, as Appl. No. 16/937,285.
Claims priority of provisional application 63/030,445, filed on May 27, 2020.
Claims priority of provisional application 62/910,650, filed on Oct. 4, 2019.
Claims priority of provisional application 62/878,964, filed on Jul. 26, 2019.
Prior Publication US 2021/0040210 A1, Feb. 11, 2021
Int. Cl. C07K 16/28 (2006.01); C07K 16/34 (2006.01)
CPC C07K 16/2809 (2013.01) [C07K 16/34 (2013.01); C07K 2317/14 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01)] 96 Claims
 
1. An isolated anti-hK2/anti-CD3 antibody comprising a first domain that binds hK2 and a second domain that binds CD3, wherein
a. the first domain that binds hK2 comprises a HCDR1, a HCDR2, a HCDR3, a LCDR1, a LCDR2 and a LCDR3 of SEQ ID NOs: 170, 171, 172, 173, 174 and 175, respectively, and the second domain that binds CD3 comprises the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of SEQ ID NOs: 255, 256, 257, 258, 259 and 261, respectively; and/or
b. the first domain that binds hK2 comprises a VH of SEQ ID NO: 162 and a VL of SEQ ID NO: 163, and the second domain that binds CD3 comprises a scFv of SEQ ID NO: 331; and/or
c. the isolated anti-hK2/anti-CD3 antibody comprises a HC1 of SEQ ID NO: 354, a LC1 of SEQ ID NO: 221 and a HC2 of SEQ ID NO: 360.